Comparative Pharmacology
Head-to-head clinical analysis: AMBISOME versus EXTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBISOME versus EXTINA.
AMBISOME vs EXTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
None Documented
None Documented
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Category C
Category C
Antifungal
Antifungal